CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (184)	3/3/2004 7:29:35 PM
From: scaram(o)uche	of 411

emphasis mine, for ACC..... Abstract Title: Initial Results Regarding the Safety, Tolerability, and Hemodynamic Effects of CVT-3146, a Selective Adenosine A2A Agonist, in Patients Undergoing Pharmacologic Stress SPECT Myocardial Perfusion Imaging Presentation Start: Tuesday, Mar 09, 2004, 4:00 PM - 5:00 PM Topic: Nuclear Cardiology/PET Author Block: Robert C. Hendel, John J. Mahmarian, Timothy M. Bateman, Manuel D. Cerqueira, Ami E. Iskandrian, Markus Jerling, Hisham Y. Abdallah, Jeffrey A. Leppo, Rush University Medical Center, Chicago, IL Abstract Title: Differential Vasodilatory Effects of CVT-3146, an A2A Adenosine Receptor Agonist in Various Vascular Beds in Anesthetized Dogs Presentation Start: Tuesday, Mar 09, 2004, 4:00 PM - 5:00 PM Topic: Nuclear Cardiology/PET Author Block: Arvinder K. Dhalla, Jiang Xu, William Kussmaul, Peter P. Kurnik, Amir Pelleg, Luiz Belardinelli, CV Therapeutics, Inc, Palo Alto, CA, Drexel University, College of Medicine, Philadelphia, PA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next